Previous studies have shown high expression of PD-L1 in tumor cells from NSCLC patients, and CAR-T cells secreting an anti-PD-L1 antibody have shown promising efficacy in humanized mouse models [71]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.